海辰药业 (300584)
Nanjing Hicin Pharmaceutical CO.,LTD.
K-Line Chart
No K-line data available
Company NameNanjing Hicin Pharmaceutical Co., Ltd.
Listing Date2017-01-12
Issue Price11.11RMB
Registered Capital1200010k RMB
Legal RepresentativeCao Yuping
Registered AddressNo. 1 Hengfa Road, Nanjing Economic and Technological Development Zone, Jiangsu Province
IndustryChemical Pharmaceuticals
Main BusinessResearch, development, production, and sales of chemical pharmaceuticals
Company ProfileNanjing Hicin Pharmaceutical Co., Ltd. was established in 2003 and is located in Nanjing Economic and Technological Development Zone. It is a high-tech enterprise integrating pharmaceutical R&D, production, and marketing. The company has GMP-standard workshops for lyophilized powder injections, small-volume injections, cephalosporin powder injections, solid preparations, and active pharmaceutical ingredients (APIs). Its product portfolio covers cardiovascular and cerebrovascular, digestive, endocrine, anti-infective, and immunology fields, with over 60 representative varieties available for production. The company has successively launched several clinically essential products to the market, including Torasemide for Injection, Cefotiam for Injection, Vidarabine Monophosphate for Injection, Ganciclovir Sodium for Injection, Cefoxitin Sodium for Injection, Tigecycline for Injection, and Lansoprazole for Injection.
Stock Details
1. Key Indicators
- Total Shares(W): 12000.00
- Circulating A-Shares(W): 8211.07
- Earnings Per Share(RMB): 0.2723
- Net Assets Per Share(RMB): 8.6944
- Operating Revenue(W RMB): 47152.69
- Total Profit(W RMB): 3485.00
- Net Profit Attributable to Parent(W RMB): 3267.85
- Net Profit Growth Rate(%): 16.22
- Weighted Return on Equity(%): 3.1600
- Operating Cash Flow Per Share(RMB): 0.4870
- Undistributed Profit Per Share(RMB): 5.4282
- Capital Reserve Per Share(RMB): 1.7612
2. Main Business
The main business covers:
- Chemical preparations
- Active pharmaceutical ingredients (APIs)
- Intermediates
- Research & development, production, and sales
3. Company Basic Information
- Company Name: Nanjing Hicin Pharmaceutical Co., Ltd.
- Listing Date: 2017-01-12
- Industry: Pharmaceutical Manufacturing
- Address: No. 1 Hengfa Road, Nanjing Economic and Technological Development Zone, Jiangsu Province, China
- Website: www.hicin.cn
- Company Profile: The company's predecessor, Nanjing Hicin Pharmaceutical Consulting Co., Ltd., was established on January 15, 2003. It was restructured into Nanjing Hicin Pharmaceutical Co., Ltd. on June 5, 2013. The company is primarily engaged in the R&D, production, and sales of chemical preparations, APIs, and intermediates.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | China Europe Enjoy Life Mixed Securities Investment Fund A Class | Fund | 93.70 | 1.14 |
| 2 | Hua'an Medicine & Biology Equity Initiated Securities Investment Fund A Class | Fund | 89.03 | 1.08 |
| 3 | Fullgo Steady Growth Mixed Securities Investment Fund A Class | Fund | 70.00 | 0.85 |
| 4 | China National Petroleum Corporation Enterprise Annuity Plan - Industrial and Commercial Bank of China Limited | Annuity | 60.50 | 0.74 |
| 5 | Yongying New Materials Intelligent Selection Mixed Initiated Securities Investment Fund A Class | Fund | 48.24 | 0.59 |
| 6 | Southern Innovation Drive Mixed Securities Investment Fund A Class | Fund | 40.08 | 0.49 |
| 7 | Southern Zhuoyuan Bond Securities Investment Fund A Class | Fund | 30.42 | 0.37 |
| 8 | Southern Rongguang Flexible Allocation Mixed Securities Investment Fund A Class | Fund | 5.66 | 0.07 |
| 9 | Southern Haowen Preferred 9-Month Holding Period Mixed Fund of Funds (FOF) A Class | Fund | 1.22 | 0.01 |
| 10 | Southern Kangle Pension Target Date 2045 Three-Year Holding Period Mixed Initiated Fund of Funds (FOF) A Class | Fund | 0.60 | 0.01 |
5. Concept Sectors
- Lithium Battery
- Solid-State Battery
- Helicobacter Pylori
- Assisted Reproduction
- Hepatitis Concept
- Innovative Drug
- Fund Increased Holdings
- Small Cap Non-Margin
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information